Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firdapse in patients treated with Botox
NCT05769478Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amifampridine in botulism, sponsored by Wake Forest University Health Sciences. Primary endpoints: Percentage of abnormal pairs at 3 hours, Percentage of Jitter at 3 hours and 1 more. Started Sep 2023; status: completed.
02
Drugs
amifampridine
03
Conditions
botulism
Beyond the preview
Go deeper on NCT05769478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769478.